Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.

Upadacitinib effectively treated severe hair loss in a child.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This paper discusses the molecular basis of intestinal regeneration and highlights the potential role of echinoderms in enhancing regenerative biology research, but reports no new research findings.

Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This study observed that using ex vivo gene therapy to modify skin cells in a pre-graft model improved dermal-epidermal junction adhesion strength and maintained collagen production over time, suggesting a potential treatment approach for recessive dystrophic epidermolysis bullosa skin wounds.

This study found that patients with severe alopecia areata are willing to accept increased risks of serious infection, cancer, and blood clots when opting for a higher dose of ritlecitinib, valuing the potential for greater hair regrowth efficacy compared to a lower dose.

This study used molecular docking simulations to identify approved drugs, including Bedaquiline and Telmisartan, with potential to treat Onchocerca volvulus infections by inhibiting key protein targets, suggesting these drugs could be repurposed for onchocerciasis treatment with further validation.

This case report highlights a rare instance of severe multi-organ involvement following a single dose of methotrexate for ectopic pregnancy, requiring intensive care but ultimately successfully treated with leucovorin and supportive care.

This article discusses the use of cetuximab for recurrent squamous cell skin cancer in palliative care, noting good responses but frequent cutaneous side effects; it presents no new findings.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This study found that both ruxolitinib and tofacitinib were effective in promoting hair regrowth for patients with severe alopecia areata, with no significant difference in efficacy and relapse rate between them, and both were well tolerated throughout the treatment.

This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.

Bempikibart may help regrow hair in people with alopecia areata.

This study found that dermatologic adverse events are common in children taking MEK inhibitors, with selumetinib patients experiencing less severe reactions and a lower risk of dosage adjustments. Age was noted as a factor in the likelihood of specific skin reactions.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

This study suggests that finasteride may upregulate BTG2 and CD244 gene expression through differential methylation, indicating potential as a treatment avenue for medulloblastoma.

This study found that etoposide enhances the radiosensitivity of CT26 colorectal adenocarcinoma in BALB/c mice, significantly inhibiting tumor growth without significant toxicity.

This study identifies two previously unreported pathogenic RIPK4 gene variants, suggesting a functional link with cell adhesion molecules in ectodermal dysplasias.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

This study found that combining hair transplantation with platelet-rich plasma led to significantly better outcomes, such as reduced hair loss area and increased hair regeneration, compared to hair transplantation alone in patients with androgenic alopecia.

This study reports that while primary treatment for uveal melanoma has a very high success rate, treating distant metastases, particularly in the liver, remains challenging. Tebentafusp, dependent on HLA-A expression, is the first drug to extend patient survival.

This study observed that the ethyl acetate extract of Equisetum debile showed high activity against 5α-reductase and lipid peroxidation with no cytotoxicity on dermal papilla cells.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

This study reviewed the genetic and phenotypic aspects of Olmsted syndrome, highlighting pathogenic mutations in TRPV3 and MBTPS2 genes and their association with specific skin manifestations like symmetrical keratoderma and hyperkeratotic plaques.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.